Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gresonitamab (AMG 910) in CLDN18.2+ Gastric/GEJ Adenocarcinoma
NCT04260191Phase 1Terminated
- Sponsor
- Amgen
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of gresonitamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicity and Treatment-emergent Adverse Events. Started Jun 2020; status: terminated.
02
Drugs
gresonitamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04260191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260191.